Next Article in Journal
Influence of ROCK Pathway Manipulation on the Actin Cytoskeleton Height
Previous Article in Journal
Epiregulin as an Alternative Ligand for Leptin Receptor Alleviates Glucose Intolerance without Change in Obesity
Previous Article in Special Issue
Oncofetal Protein CRIPTO Is Involved in Wound Healing and Fibrogenesis in the Regenerating Liver and Is Associated with the Initial Stages of Cardiac Fibrosis

Therapeutic Targeting of Intestinal Fibrosis in Crohn’s Disease

First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, 27100 Pavia, Italy
Author to whom correspondence should be addressed.
Academic Editors: Maurizio Onisto and Valentina Masola
Cells 2022, 11(3), 429;
Received: 22 December 2021 / Revised: 21 January 2022 / Accepted: 24 January 2022 / Published: 26 January 2022
(This article belongs to the Special Issue Molecular Mechanisms in Organ Fibrosis)
Intestinal fibrosis is one of the most threatening complications of Crohn’s disease. It occurs in more than a third of patients with this condition, is associated with increased morbidity and mortality, and surgery often represents the only available therapeutic option. The mechanisms underlying intestinal fibrosis are partly known. Studies conducted so far have shown a relevant pathogenetic role played by mesenchymal cells (especially myofibroblasts), cytokines (e.g., transforming growth factor-β), growth factors, microRNAs, intestinal microbiome, matrix stiffness, and mesenteric adipocytes. Further studies are still necessary to elucidate all the mechanisms involved in intestinal fibrosis, so that targeted therapies can be developed. Although several pre-clinical studies have been conducted so far, no anti-fibrotic therapy is yet available to prevent or reverse intestinal fibrosis. The aim of this review is to provide an overview of the main therapeutic targets currently identified and the most promising anti-fibrotic therapies, which may be available in the near future. View Full-Text
Keywords: antifibrotic therapy; Crohn’s disease; IBD; intestinal fibrosis; stricture antifibrotic therapy; Crohn’s disease; IBD; intestinal fibrosis; stricture
Show Figures

Figure 1

MDPI and ACS Style

Santacroce, G.; Lenti, M.V.; Di Sabatino, A. Therapeutic Targeting of Intestinal Fibrosis in Crohn’s Disease. Cells 2022, 11, 429.

AMA Style

Santacroce G, Lenti MV, Di Sabatino A. Therapeutic Targeting of Intestinal Fibrosis in Crohn’s Disease. Cells. 2022; 11(3):429.

Chicago/Turabian Style

Santacroce, Giovanni, Marco V. Lenti, and Antonio Di Sabatino. 2022. "Therapeutic Targeting of Intestinal Fibrosis in Crohn’s Disease" Cells 11, no. 3: 429.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop